– CANADA, Vancouver – Pacgen Life Science Corporation (TSX-V:PBS) announced that Dr. Rakesh Arya has been appointed to its Board of Directors. Dr. Arya brings to Pacgen over twenty-five years of business management experience gained primarily in the dentistry field. As a dentist and an entrepreneur, he has built a keen interest in business development, innovation, and management. Dr. Arya currently serves as the principal of a high-tech dentistry clinic based in Canada. Coming from a family of medical professionals, Dr. Arya has practiced dentistry since 1990 and served in the communities of different countries before setting down in Canada. He is well connected to medical and pharmacy professions in North America and South-East Asia. Dr. Arya holds a Dentistry Degree from University of Toronto, Canada, a Master Degree in Hospital Management from Chennai University, India, and a Master Degree in Dentistry (Orthodontics) from Government Dental College and Hospital, India.
Pacgen is a life sciences company focused on building a global commercial platform to market innovative consumer health products developed by SMEs in North America. Currently, the Company has marketing rights to four distinctive brands with over seventy different products in two reportable market segments, including oral care and skin care. These products marketed under the tradenames of P113+, DermaMed, DermaSoleil and Deserving Health have reached markets in Asia and North America.
For more information : http://www.pacgenlife.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.